Business
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues;
About this update from Arvinas, Inc.
[{"type":"text","content":"– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –\n – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020 – – Arvinas and Pfizer enter collaboration and supply agreement; initiation of Phase 1b combination of ARV-471 and Ibrance® expected in the fourth quarter of 2020 – NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. “Beginning the Phase 2 portion of the ARV-110 clinical trial marks another significant milestone for Arvinas,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas. “Together with the expected initiation of a cohort expansion of ARV-471 in combination with a CDK4/6 inhibitor before the end of the year, we’re gratified by the strong momentum of our lead programs heading into 2021.” “When combined with our recent disclosure of five additional programs in our preclinical pipeline, these clinical milestones further validate our PROTAC® Discovery Engine and the opportunity to create PROTAC® degraders that meaningfully improve patient care,” added Dr. Houston. Business Highlights and Recent Developments Dose escalation in each of the Phase 1/2 clinical trials of ARV-110 and ARV-471 continues.Arvinas has initiated dosing at a first dose level in a Phase 2 cohort expansion for ARV-110.The company announced platform updates and disclosed five additional programs from its preclinical pipeline. Arvinas’ portfolio encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience. The newly disclosed programs were B-cell lymphoma 6 protein (BCL6), Kirsten rat sarcoma (KRAS) protein, c-Myc, hematopoietic progenitor kinase 1 (HPK1), and mutant huntingtin (mHTT).Arvinas entered into a collaboration and supply agreement with Pfizer in connection with a planned Phase 1b cohort expansion evaluating ARV-471 in combination with Pfizer’s Ibrance® (palbociclib), an oral CDK4/6 inhibitor. Anticipated Milestones and Expectations 2020 Milestones and Expectations Arvinas expects to provide a program update for ARV-110, including a Phase ...